6Jensen RL. Growth factor - mediated angiogenesis in the malignant progression of glial tumors:a review. Surg Neurol, 1998;49(1):189-- 196.
7Turner HE , et al. Angiogenesis in pituitary adenomas - relationship to endocrine function, treamaent and outcome. Journal of Endocrinology, 2000; 165(2) :475-481.
8Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings . Neurosurgery, 1993;33 (4):610--618.
9Weidner N. Intratumor microvessel density as prognosic factor in cancer. Am J Pathol, 1995;147(1):9~19.
10Folkman J. Tumor angiogenesis: Therapeutic implication . N Eag J Med, 1971 ;285(22) : 1182-1186.
1Folkman J. Angiogenesis and angiogenesis inhibition: an overview[J]. EXS, 1997,79 : 1-8.
2Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J]. Cell, 1996,86 (3) :353-364.
3Weidner N, Folkman J, Pozza F. Tumor angiogensis: a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Natl Cancer Inst, 1992,84 (24): 1875- 1887.
4Maeda K, Chung Y S, Ogawa Y. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma[J]. Cancer, 1996,77(5) :858-863.
5Shin S, Sung B J, Cho Y S, et al. An anti-apoptorie protein human survivin is a direct inhibitor of caspase-3 and -T[J]. Biochemistry,2001,40(4) : 1117-1123.
6Wurl P, Kappler M, Meye A, et al. Co-expression of survivin and TERT and risk of turnout-related death in patients with soft- tissue sarcoma[J]. Lancet,2002,359(9310) :943-945.
7Tan G, Cioc A M, Perez Montie D, et al. Microvascular density dose not correlate with histopathology and outcome in neuroendocrine tumors of the pancereas [J]. Appi Immunohistochem Mol Morphol, 2004,12 ( 1 ): 31-35.
8Hannen E J, Riediger D. The quantification of angiogenesis in relation to metastasis in oral cancer: a review[J]. Int J Oral Maxillofac Surg,2004,33(1) 12-7.
